CGEM vs. BEAM, DYN, APGE, TWST, TVTX, BHVN, IMCR, CDTX, AUPH, and WVE
Should you be buying Cullinan Therapeutics stock or one of its competitors? The main competitors of Cullinan Therapeutics include Beam Therapeutics (BEAM), Dyne Therapeutics (DYN), Apogee Therapeutics (APGE), Twist Bioscience (TWST), Travere Therapeutics (TVTX), Biohaven (BHVN), Immunocore (IMCR), Cidara Therapeutics (CDTX), Aurinia Pharmaceuticals (AUPH), and WAVE Life Sciences (WVE). These companies are all part of the "pharmaceutical products" industry.
Cullinan Therapeutics vs. Its Competitors
Beam Therapeutics (NASDAQ:BEAM) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.
99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 3.5% of Beam Therapeutics shares are owned by company insiders. Comparatively, 7.2% of Cullinan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Cullinan Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -661.31%. Cullinan Therapeutics' return on equity of -36.56% beat Beam Therapeutics' return on equity.
In the previous week, Cullinan Therapeutics had 4 more articles in the media than Beam Therapeutics. MarketBeat recorded 10 mentions for Cullinan Therapeutics and 6 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 0.62 beat Cullinan Therapeutics' score of 0.33 indicating that Beam Therapeutics is being referred to more favorably in the media.
Cullinan Therapeutics has lower revenue, but higher earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.
Beam Therapeutics currently has a consensus price target of $48.45, indicating a potential upside of 191.40%. Cullinan Therapeutics has a consensus price target of $26.80, indicating a potential upside of 227.23%. Given Cullinan Therapeutics' higher possible upside, analysts plainly believe Cullinan Therapeutics is more favorable than Beam Therapeutics.
Beam Therapeutics has a beta of 2.22, suggesting that its share price is 122% more volatile than the S&P 500. Comparatively, Cullinan Therapeutics has a beta of -0.08, suggesting that its share price is 108% less volatile than the S&P 500.
Summary
Beam Therapeutics and Cullinan Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Cullinan Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CGEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cullinan Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CGEM) was last updated on 8/22/2025 by MarketBeat.com Staff
MarketBeat All Access